Propanc Bio Stock Price, News & Analysis

Propanc Biopharma (Nasdaq: PPCB) has requested a foreign filing license from Spain for two provisional patents covering methods to treat resistant cancer and fibrosis. The provisional patents will be filed with IP Australia under Propanc Pty Ltd and are expected to be pursued in key global jurisdictions.

The fibrosis provisional is described as a world-first expansion of PRP proenzyme therapy beyond cancer. Propanc says its planned Phase 1b First‑In‑Human study in 2026 will define PRP dosing ahead of Phase 2 proof‑of‑concept studies.

Propanc Biopharma (Nasdaq: PPCB) provided a corporate update and reported Q1 2025/26 results for the quarter ended Sept 30, 2025. Key operational progress includes advancing PRP toward a planned Phase 1b first-in-human study in 30–40 patients in 2026, GMP manufacturing scale-up with purification achieving >95% purity, and Rec-PRP synthetic program moving to formal preclinical development after potency evaluation. IP activity includes multiple patent drafts and a proposed 12‑month extension of the POP1 research program with Universities of Jaén and Granada. Financings: a closed underwritten public offering of 1,000,000 shares at $4.00 ($4.0M gross), Nasdaq trading began Aug 15, 2025, and a $100M private placement facility with an initial $1M tranche received. Quarter-end cash was $600,000 with total current assets of $17M.

Propanc Biopharma (Nasdaq: PPCB) entered a securities purchase agreement with Hexstone Capital for a private placement of up to $100.0 million in Series C convertible preferred stock to support a digital asset acquisition strategy and accelerate R&D. The company received an initial $1.0 million on closing via 100 Series C shares with an initial stated value of $10,000 each.

Propanc issued 9,900 warrants exercisable immediately for one preferred share at $10,000 per share (up to $99.0 million); warrants expire in 12 months. Company expects PRP to enter a First‑In‑Human study in H2 2026. Monthly call feature allows up to 500 warrants to be called per month at $0.01.

Propanc Biopharma (NASDAQ: PPCB) announced a strategic initiative on Nov 4, 2025 to pursue acquisitions of Digital Asset Treasury (DAT) companies trading below Market Cap to Net Asset Value (MNAV). Management said acquiring undervalued DATs could strengthen Propanc's balance sheet, diversify assets, and create long-term shareholder value while the company continues its oncology development work.

The release cites public data showing Bitcoin treasury companies hold approximately $76.9 billion and Ethereum-based DATs hold about $17.6 billion in digital assets. Propanc's board is evaluating targets and building due diligence frameworks and will update shareholders as qualified targets are identified.

Propanc Biopharma (PPCB) announced a strategic financing agreement with Hexstone Capital on October 15, 2025 providing up to $100 million of potential funding.

Key terms include issuance of 100 shares of Series C Convertible Preferred Stock for an initial $1.0 million (stated value $10,000 each) convertible at an initial price of $5.00 per share (a 280% premium to the recent $1.78 close). Propanc also issued 9,900 warrants to buy Preferred Stock at $9,999.99 each (up to $99 million), exercisable immediately for 12 months. The conversion includes variable alternative prices and a 4.99% beneficial ownership limitation. The agreement allows the company to call up to 500 warrants per month for $0.01 each (up to $5 million preferred stock per month), subject to equity and ownership limits. SEC Form 8-K contains full details.

Propanc Biopharma (PPCB) entered a strategic financing agreement with Hexstone Capital on Oct 15, 2025 for up to $100 million in potential funding.

Under the terms, Propanc will issue 100 shares of Series C Convertible Preferred Stock for an initial stated value of $10,000 each (initial investment $1 million). The Preferred is convertible at an initial price of $5.00 per share. The release describes that conversion price as a 280% premium in the headline and a 28% premium in the body versus a recent closing price of $1.78. Propanc also issued 9,900 warrants exercisable immediately to buy Preferred Stock at $9,999.99 each, representing up to $99 million of additional funding; warrants expire in 12 months. The agreement includes a 4.99% beneficial ownership limit and a company option to call up to 500 warrants per month at $0.01, enabling up to $5 million of Preferred issuance per month, subject to equity conditions. More details are in the company Form 8-K filed with the SEC.

Propanc (NASDAQ:PPCB) filed its annual 10-K for the year ended June 30, 2025 and reported major year‑end changes after an IPO and Nasdaq uplisting on August 14, 2025. Key reported items include total assets rising to $19.6 million (from ~ $72,000), stockholders' equity improving to $13.9 million (from a $3.8 million deficit), and a completed offering of 1,000,000 common shares generating $4.0 million gross. Management said development milestones for the lead therapeutic are anticipated by end of 2025 and through 2026, and the company intends to establish a $100 million or greater digital asset treasury within 12 months. The asset growth was attributed primarily to prepaid service contracts supporting market awareness, advisory, accounting, manufacturing, and R&D activities.

Propanc Biopharma (Nasdaq: PPCB) has received a certificate of grant from the USPTO for its "proenzyme composition" patent, marking its fourth US patent. The patent specifically covers a future clinical dose of PRP, the company's lead asset targeting metastatic cancer treatment.

The company's IP portfolio now includes 90 patents filed in major jurisdictions. PRP is targeting the global metastatic cancer treatment market, projected to reach $111.2 billion by 2027. The treatment works by inducing cell differentiation rather than directly killing cancer cells, offering a relatively non-toxic approach to treating metastatic cancer from solid tumors.

Propanc plans to commence a Phase 1B First-In-Human study next year and is pursuing capital raising initiatives, including a digital asset diversification strategy.

Propanc Biopharma (NASDAQ:PPCB), a biopharmaceutical company focused on cancer treatments, has announced plans to acquire $100 million worth of Ethereum over the next 12 months. This strategic move is part of a multi-faceted approach combining cryptocurrency exposure, pharmaceutical drug development, and asset acquisition.

The company aims to leverage Ethereum's advantages, including smart contracts, DApps capabilities, and its proof of stake mechanism. The strategy is designed to address cash flow needs during pre-revenue stage, diversify assets, and accelerate growth potential. Comparative data shows Ethereum's significant outperformance, with 5-year returns exceeding 1,000% compared to traditional indices like S&P 500 (86%) and Nasdaq (305%).